Overview

A Clinical Study to Evaluate the Efficacy, Safety, and Tolerability of TERN-601 in Adults With Overweight or Obesity

Status:
ACTIVE_NOT_RECRUITING
Trial end date:
2026-12-01
Target enrollment:
Participant gender:
Summary
This is a Phase 2a multicenter, randomized, double-blind, placebo-controlled clinical trial studying the efficacy, safety, and tolerability of orally administered TERN-601 in adults with overweight or obesity.
Phase:
PHASE2
Details
Lead Sponsor:
Terns, Inc.